DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
暂无分享,去创建一个
Wei Yuan | Nina Tunariu | Rosalind Eeles | Alan Ashworth | Robert Jones | Jane Goodall | Arul M Chinnaiyan | Gerhardt Attard | Mark A Rubin | Emma Hall | Xuhong Cao | Johann S de Bono | Roger A'Hern | A. Ashworth | M. Rubin | A. Chinnaiyan | R. Eeles | Xuhong Cao | N. Tunariu | F. Feng | D. Robinson | R. A’Hern | C. Lord | K. Knudsen | A. Swain | E. Hall | R. Ferraldeschi | Robert J. Jones | T. Elliott | Yi-Mi Wu | L. Kunju | P. Flohr | G. Boysen | J. D. de Bono | G. Attard | S. Miranda | Z. Zafeiriou | J. Mateo | R. Perez-Lopez | H. Pemberton | J. Goodall | S. Carreira | S. Sandhu | A. Protheroe | Penny Flohr | Yi-Mi Wu | Suneil Jain | Christopher J Lord | R. Brough | W. Yuan | C. Ralph | D. Bianchini | A. Omlin | I. Figueiredo | R. Riisnaes | Felix Y Feng | Andrew Protheroe | Karen E Knudsen | Aurelius Omlin | N. Porta | Lakshmi P Kunju | Roberta Ferraldeschi | D. Roda | Amanda Swain | Tony Elliott | Dan Robinson | Susana Miranda | Zafeiris Zafeiriou | Joaquin Mateo | Raquel Perez-Lopez | Rachel Brough | Ruth Riisnaes | D. Nava Rodrigues | Claire Paulding | Gunther Boysen | Suzanne Carreira | Shahneen Sandhu | Helen Mossop | Daniel Nava Rodrigues | Nuria Porta | Alexa Gillman | Ines Figueiredo | George Seed | Christy Ralph | Syed Hussain | Ursula McGovern | Diletta Bianchini | Chris T Williamson | Bernardette Ebbs | Gemma Fowler | Desamparados Roda | Helen Pemberton | A. Gillman | G. Seed | S. Hussain | U. McGovern | S. Jain | H. Mossop | Gemma Fowler | C. Williamson | C. Paulding | Bernardette Ebbs | Alexa Gillman | Daniel Nava Rodrigues | Xuhong Cao | R. Pérez-López
[1] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2007, Nature.
[2] Y. Shiloh,et al. Fragments of ATM which have dominant-negative or complementing activity , 1997, Molecular and cellular biology.
[3] Y Taya,et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. , 1998, Science.
[4] A. Ashworth,et al. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] J. Sambrook,et al. Dominant negative ATM mutations in breast cancer families. , 2002, Journal of the National Cancer Institute.
[6] G. Kroemer,et al. Predictive biomarkers for cancer therapy with PARP inhibitors , 2014, Oncogene.
[7] R. Eeles,et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[9] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[10] P. Kantoff,et al. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] K. Pienta,et al. The Current State of Hormonal Therapy for Prostate Cancer , 2002, CA: a cancer journal for clinicians.
[12] A. Sivachenko,et al. Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.
[13] D. Matei,et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.
[14] Mohammad Hassan Murad,et al. Early detection of prostate cancer: AUA Guideline. , 2013, The Journal of urology.
[15] Alan Ashworth,et al. Translating cancer research into targeted therapeutics , 2010, Nature.
[16] T. Yap,et al. Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail , 2014, British Journal of Cancer.
[17] Y. Pommier,et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.
[18] D. Easton,et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients , 2011, British Journal of Cancer.
[19] Tomasz Burzykowski,et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Ayala Hubert,et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Benjamin J. Raphael,et al. The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.
[22] B. Price,et al. Activation of p53 transcriptional activity requires ATM's kinase domain and multiple N-terminal serine residues of p53 , 2001, Oncogene.
[23] Bing Xia,et al. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination , 2010, Nature Structural &Molecular Biology.
[24] A. D’Andrea,et al. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. , 2015, Cancer research.
[25] Alan Ashworth,et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.
[26] O. Goodman,et al. Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP , 2014, Molecular Cancer Research.
[27] S. Adimoolam,et al. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination , 2007, Proceedings of the National Academy of Sciences.
[28] D. Matei,et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial , 2014 .
[29] Manash S. Chatterjee,et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. , 2013, The Lancet. Oncology.
[30] N. Ellis,et al. Functional Link between BLM Defective in Bloom's Syndrome and the Ataxia-telangiectasia-mutated Protein, ATM* , 2002, The Journal of Biological Chemistry.
[31] F. Demichelis,et al. Tumor clone dynamics in lethal prostate cancer , 2014, Science Translational Medicine.
[32] D. Dearnaley,et al. PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate , 2015, European urology.
[33] J. Thigpen. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer , 2012 .
[34] S. Jackson,et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining , 2010, Nature Structural &Molecular Biology.
[35] Sam S. Chang,et al. Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States. , 2015, The Journal of urology.
[36] William Berry,et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] M. Okada,et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.
[38] Jan Lubinski,et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] M. Rubin,et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. , 2013, European urology.
[40] M. Kastan,et al. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation , 2003, Nature.
[41] P. Munster,et al. Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling , 2013, Molecular Cancer Therapeutics.
[42] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Lawrence D. True,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.
[44] A. Schäffer,et al. Atm haploinsufficiency results in increased sensitivity to sublethal doses of ionizing radiation in mice , 1999, Nature Genetics.